The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Solvay Pharmaceuticals
Approval Status: Approved March 1998
Treatment for: prevention of osteoporosis
General Information
Estratab (.3 mg ) has been approved for the prevention of osteoporosis.
Clinical Results
In a two-year clinical trial, women on .3 mg Estratab tablets showed increased bone mineral density over baseline in the spine, hip, and whole body.
Side Effects
Women taking this low dose also experienced fewer side effects, such as headache, nausea, breast tenderness, and vaginal bleeding, than women on higher doses.
